Cyrano Therapeutics
PrivateLast Round
Series B
Jan 16, 2024
Est. Valuation
$40M
Total Funding Raised
$21.8M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Cyrano Therapeutics operates in Healthcare & Life Sciences and is based in Delray Beach, Florida. Its latest recorded funding round was a Series B round in January 2024.
Cyrano Therapeutics is a biotechnology company developing a nasal spray designed to restore smell and taste in individuals who have lost these senses due to viral infections or neurological conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical Devices, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cyrano Therapeutics Comparables
Compare Cyrano Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Senvera Therapeutics | 81% | |
| Mirodia Therapeutics | 79% | |
| Lyra Therapeutics | 55% |
For institutional investors. Book with your work email.
Cyrano Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 16, 2024 | ||||
| Series A | Dec 10, 2020 |
For institutional investors. Book with your work email.
Cyrano Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Remiges Ventures | Series B, Series A |
| DeepWork Capital | Series B |
| Lumira Ventures | Series B, Series A |
| DNV Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 41% MoM.
- Jul 26, 2026
Monthly visitors increased 53% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 8, 2026
Cyrano Therapeutics, Inc. has an abstract detailing Phase 2 FLAVOR trial results accepted for an oral presentation at the 72nd Annual Meeting of the ARS in California in Oct '26.
For institutional investors. Book with your work email.
Cyrano Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cyrano Therapeutics's valuation, stock price, and market status.
Is Cyrano Therapeutics a public or private company?
Cyrano Therapeutics is a private company.
What is the current stock price of Cyrano Therapeutics?
Cyrano Therapeutics is a private company, so its shares have no public market price. Caplight tracks Cyrano Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cyrano Therapeutics worth (valuation)?
Cyrano Therapeutics's valuation is estimated at $40.0M based on funding round data.
Can I buy Cyrano Therapeutics stock?
Cyrano Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cyrano Therapeutics's last funding round?
Cyrano Therapeutics's most recent funding round was Series B on January 16, 2024.
Who are the main investors in Cyrano Therapeutics?
Key investors in Cyrano Therapeutics include Remiges Ventures, DeepWork Capital, Lumira Ventures.
Will Cyrano Therapeutics IPO soon?
No public IPO plans have been announced for Cyrano Therapeutics.
How can I track Cyrano Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Cyrano Therapeutics's shares on secondary markets.